Artal Group S.A. - DENALI THERAPEUTICS INC ownership

DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 213 filers reported holding DENALI THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.25 and the average weighting 0.4%.

Quarter-by-quarter ownership
Artal Group S.A. ownership history of DENALI THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$16,564
-30.1%
802,8990.0%0.71%
-3.3%
Q2 2023$23,694
+28.1%
802,8990.0%0.73%
-33.2%
Q1 2023$18,499
-16.9%
802,899
+0.4%
1.10%
-11.5%
Q4 2022$22,248
-99.9%
800,000
+33.3%
1.24%
+58.0%
Q3 2022$18,414,000
+4.3%
600,0000.0%0.79%
-16.6%
Q2 2022$17,658,000
-8.5%
600,0000.0%0.94%
+16.7%
Q1 2022$19,302,000
-27.9%
600,0000.0%0.81%
+11.3%
Q4 2021$26,760,000
+6.1%
600,000
+20.0%
0.73%
+28.7%
Q3 2021$25,225,000
-35.7%
500,0000.0%0.56%
-29.1%
Q2 2021$39,220,000
+37.4%
500,0000.0%0.80%
+57.9%
Q1 2021$28,550,000
-14.8%
500,000
+25.0%
0.50%
-29.9%
Q4 2020$33,504,000
+133.8%
400,0000.0%0.72%
+106.6%
Q3 2020$14,332,000
+31.7%
400,000
-11.1%
0.35%
+14.5%
Q2 2020$10,881,000
+24.3%
450,000
-10.0%
0.30%
-17.8%
Q1 2020$8,755,000
+25.6%
500,000
+25.0%
0.37%
+37.5%
Q4 2019$6,968,000
+13.7%
400,0000.0%0.27%
+9.3%
Q3 2019$6,128,000
-26.2%
400,0000.0%0.25%
-26.8%
Q2 2019$8,304,000
-10.6%
400,0000.0%0.34%
-11.3%
Q1 2019$9,288,000
-10.1%
400,000
-20.0%
0.38%
-1.0%
Q4 2018$10,330,000
-5.0%
500,0000.0%0.38%
+35.3%
Q3 2018$10,870,000
+42.6%
500,0000.0%0.28%
+74.7%
Q2 2018$7,625,000
-13.9%
500,000
+11.1%
0.16%
+45.9%
Q1 2018$8,861,000
+13.3%
450,000
-10.0%
0.11%
-5.9%
Q4 2017$7,820,000500,0000.12%
Other shareholders
DENALI THERAPEUTICS INC shareholders Q2 2021
NameSharesValueWeighting ↓
Crestline Management, LP 7,705,039$343,645,00025.68%
Casdin Capital, LLC 1,500,000$66,900,0001.89%
Flagship Pioneering Inc. 2,619,968$116,851,0001.81%
SECTORAL ASSET MANAGEMENT INC 189,600$8,456,0001.27%
Integral Health Asset Management, LLC 100,000$4,460,0001.23%
Temasek Holdings (Private) Ltd 5,369,487$239,479,0000.86%
Goldstream Capital Management Ltd 78,418$3,497,0000.86%
Yiheng Capital Management, L.P. 335,184$14,949,0000.76%
GILDER GAGNON HOWE & CO LLC 2,900,114$129,345,0000.74%
Artal Group S.A. 600,000$26,760,0000.73%
View complete list of DENALI THERAPEUTICS INC shareholders